Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q3 2019 · 10-Q
Revenue$379.00K$379.00K±0.0% vs Q3 2018 Net Income-$12.83M-$12.83MN/M vs Q3 2018 EPS Diluted-$0.41-$0.41N/M vs Q3 2018 Operating Income-$13,149,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-3469.4%+1238.0 pt vs Q3 2018
Net margin-3385.0%+1189.7 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end